SCHEMBL22713063

SCHEMBL22713063

O=C1C=CCCN1C(=O)C=Cc1cnn(C2CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ PSMB11 A5LHX3 1/20 0.50
▸ PSMA7 O14818 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ FOXO3 O43524 1/20 0.50
▸ MITF O75030 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ PSMB1 P20618 1/20 0.50
▸ PSMA1 P25786 1/20 0.50
▸ PSMA2 P25787 1/20 0.50
▸ PSMA3 P25788 1/20 0.50
▸ PSMA4 P25789 1/20 0.50
▸ PSMB8 P28062 1/20 0.50
▸ PSMB9 P28065 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21001970 1.00 LMNA (0.50) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL21001991 0.83 ALDH1A1 (0.44) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL22713057 0.83 ALDH1A1 (0.44) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL21002518 0.83 SMN1; SMN2 (0.57) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL21001906 0.83 SMN1; SMN2 (0.57) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL15432080 0.77 ALDH1A1 (0.64) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL21039907 0.76 ALDH1A1 (0.47) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL21001998 0.74 RAB9A (0.51) LMNAALDH1A1SMN1; SMN2HIF1ANPC1
SCHEMBL21001882 0.73 ALDH1A1 (0.57) LMNAALDH1A1TP53SMN1; SMN2CYP1A2
SCHEMBL21002134 0.73 MAPT (0.54) LMNAALDH1A1TP53SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200377510-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2020-12-03 — — US claimed
US-11485725-B2 Derivatives of piperlongumine and uses thereof AURANSA INC. (US) 2022-11-01 — — US disclosed
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2021-07-01 — — US disclosed
US-20200377510-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377510-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF SHARPIN, PIR, THPO LMNA 3475/4885ALDH1A1 421/4885TP53 1020/4885
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF THPO, PIR, PAK6 LMNA 2273/4885ALDH1A1 228/4885TP53 148/4885
US-11485725-B2 Derivatives of piperlongumine and uses thereof PIR, THPO, DHPS LMNA 2275/4885ALDH1A1 251/4885TP53 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback